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Abstract The treatment strategy for cases of combined
autoimmune hepatitis (AIH) and chronic hepatitis C (CHC)
has not yet been established. A 47-year-old woman and a
53-year-old-woman were hospitalized for treatment of
CHC. Ultrasonography and histological ﬁndings revealed
that their liver was not cirrhotic but did have chronic
damage. The histological ﬁndings of both patients were
suggestive of AIH. The patients were systematically treated
with pegylated interferon-alpha 2b plus ribavirin which
was preceded by and combined with corticosteroid (CS),
and showed sustained virological responses and normal
liver function. Although these two patients with combined
AIH and CHC were successfully treated with this regimen,
careful attention to exacerbation of hepatic inﬂammation is
needed because hepatitis C viral load was increased due to
immunosuppression during CS treatment.
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Introduction
Hepatitis C virus (HCV) infection is known to be associ-
ated with various autoimmune diseases, such as
autoimmune hepatitis (AIH), Sjo ¨gren’s syndrome, rheu-
matoid arthritis and autoimmune thyroid disorders [1].
Among AIH patients, it has been reported that at least
10 % were infected with HCV in Japan [2]. Although
corticosteroid (CS) therapy has been established as effec-
tive for AIH [3–5], there is concern about the possible
increase in HCV caused by the immunosuppressive effect
of CS in HCV-infected AIH patients. In contrast, interferon
(IFN) administration, which is effective for chronic hepa-
titis C (CHC), has been reported to initiate acute exacer-
bation of AIH [6], and sometimes fulminant hepatic failure
[7, 8]. Owing to these discordant treatment options for AIH
and CHC, the treatment decision for patients with both of
these hepatic diseases represents a dilemma.
Here we report two patients with combined AIH and
CHC who showed favorable outcomes with pegylated IFN
(PEG-IFN) plus ribavirin (RBV) therapy which was pre-
ceded by and combined with CS administration.
Case reports
Case 1
A 47-year-old woman (height 153.3 cm, weight 64.5 kg)
was referred to our hospital for treatment of CHC in
August 2006. Although she had received IFN therapy
5 years previously, eradication of HCV had not been
achieved, and her serum levels of transaminases during the
therapy had been higher than baseline.
She was not a habitual drinker, and there was no history
of blood transfusion, drug abuse or tattoos. There were no
abnormal ﬁndings in her physical examination. Blood tests
showed that the alanine aminotransferase (ALT) level
was 97 IU/L, immunoglobulin (Ig) G concentration was
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DOI 10.1007/s12328-012-0295-43457 mg/dL, anti-nuclear antibody (ANA) titer was 1:40,
liver–kidney microsomal antibody-1 (LKM-1) was nega-
tive, HCV genotype was 2a and viral load was 2700 KIU/
mL (Table 1). HLA typing showed DR4. To distinguish
between AIH and CHC, a liver biopsy was carried out
under laparoscopy. Although characteristic laparoscopic
ﬁndings for AIH of multilobular and ecchymotic red
macula, extensive recess, furrowed recess and rough and
large tuber were not seen; microscopic ﬁndings showed
considerable inﬁltration of plasma cells in portal areas and
severe interface hepatitis, which are uncommon in CHC
(Fig. 1). Therefore, we determined that the main cause of
her hepatic disorder was AIH, although the diagnostic
score according to the International Autoimmune Hepatitis
Group (IAIHG) in 1999 [9] was 12 points, deﬁned as
‘probable’ for AIH.
We started 30 mg/day prednisolone (PSL) administration
in October 2006. Although the IgG level gradually decreased
after initiation of PSL, the ALT level remained unchanged.
Serum HCV load increased to 4800 KIU/mL during PSL
administration. After 6 weeks of PSL (ALT 101 IU/L, IgG
2008 mg/dL), a weekly subcutaneous injection of 100 lg
PEG-IFN-alpha-2b and daily oral administration of 800 mg
RBV were started in combination with 20 mg/day PSL. The
ALT level decreased gradually after starting PEG-IFN plus
RBV therapy, and HCV RNA disappeared from her serum
at week 8 of PEG-IFN plus RBV therapy. Subsequently, a
sustained virological response (SVR) was achieved by
PEG-IFN plus RBV therapy for 24 weeks. PSL was con-
tinued for 4 months after cessation of PEG-IFN plus RBV,
and then withdrawn because ALT and IgG levels remained
continuously normal (ALT 13 IU/L, IgG 1472 mg/dL at the
end of PSL administration). From the end of the treatment to
the present time, her serum ALT and IgG levels have been
within the normal ranges for 3 years without any medication
(Fig. 2).
Case 2
Case 2 was a 53-year-old woman (height 159 cm, weight
56.6 kg). She was diagnosed with CHC at 39 years of age,
but had not taken any medication because of low serum
Table 1 Laboratory data on
admission (Case 1)
ANA anti-nuclear antibody,
ASMA anti-smooth muscle
antibody, LKM-1 Ab liver-
kidney microsomal antibodies
type 1, AMA antimitochondrial
antibody
WBC 4600/lL Total protein 8.2 g/dL IgG 3457 mg/dL
RBC 434 9 10
4/lL Albumin 3.8 g/dL IgA 299 mg/dL
Hb 13.1 g/dL c-globulin 31.9 % IgM 47 mg/dL
Ht 39.4 % AST 82 IU/L ANA 40 times
Platelet 14.7 9 10
4/lL ALT 97 IU/L ASMA (-)
LDH 226 IU/L LKM-1 Ab (-)
ALP 225 IU/L AMA (-)
cGTP 48 IU/L HBs Ag (-)
Total bilirubin 0.7 mg/dL HBc Ab (-)
Cholinesterase 266 IU/L HCV-RNA 2700 KIU/mL
Genotype 2a
HLA-DR 4, 9
Fig. 1 Histological ﬁndings of Case 1 show considerable inﬁltration of plasma cells in portal areas and severe interface hepatitis. a H&E 940,
b H&E 9400
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January 2008, and she was diagnosed with Sjo ¨gren’s syn-
drome and mixed connective tissue disease based on the
symptoms and serological tests, by a specialist in collagen
diseases. Her hepatic function worsened after oral admin-
istration of pilocarpine hydrochloride, therefore, she was
referred to our department.
She had a history of transfusion of blood coagulation
factors during childbirth. Laboratory tests showed that the-
ALT level was 128 IU/L, IgG level was 1933 mg/dL, ANA
titer was 1:1280, LKM-1 was negative, HLA typing showed
DR9 and DR15, HCV genotype was 1b and viral load was
3.3 log IU/mL (Table 2). Histological ﬁndings of a liver
biopsy specimen showed moderate inﬁltration of lympho-
cytes and plasma cells in portal areas, interface hepatitis and
rosette formation, which are typical AIH characteristics
(Fig. 3). Although the score according to the simpliﬁed
criteria of AIH (IAIHG 2008) [10] was 6 points, which
means ‘probable’ for AIH, we judged that her hepatic dis-
order was mainly caused by AIH, similar to Case 1.
After starting oral administration of 40 mg PSL
(0.7 mg/kg) in February 2009, her ALT and IgG levels
immediately decreased and became normalized. Serum
HCV load increased to 5.6 log IU/mL during PSL admin-
istration. After PSL administration for 13 weeks, with a
gradual decrease in dose, a weekly subcutaneous injection
of 80 lg PEG-IFN-alpha-2b and daily oral 600 mg RBV
were started in combination with 20 mg/day PSL. HCV
RNA disappeared from her serum at week 8 of PEG-IFN
plus RBV therapy, and an SVR was achieved by continuing
the treatment for 48 weeks. After the end of the PEG-IFN
plus RBV therapy, PSL dose was gradually decreased and
PSL 30mg/day
Ribavirin 800mg/day
Peg-IFNα2b 100µg/week
Liver biopsy
100
200
300 4500
3000
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ALT
IU/L
IgG
mg/dL
IgG
ALT
24 weeks
20mg/day
HCV-RNA
KIU/ml
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2700
Peg-IFN/Ribavirin  0W 4W 8W 24W after 6 M 
4800 0.5 negative negative negative
Fig. 2 Clinical course of
Case 1
Table 2 Laboratory data on
admission (Case 2)
ANA anti-nuclear antibody,
ASMA anti-smooth muscle
antibody, LKM-1 Ab liver-
kidney microsomal antibodies
type 1, AMA antimitochondrial
antibody
WBC 3600/lL TP 7.3 g/dL IgG 1933 mg/dL
RBC 463 9 10
4/lL Albumin 3.9 g/dL IgA 322 mg/dL
Hb 13.5 g/dL c-globulin 25.5 % IgM 156 mg/dL
Ht 40.4 % AST 108 IU/L ANA 1280 times
Platelet 15.1 9 10
4/lL ALT 128 IU/L ASMA (-)
LDH 269 IU/L LKM-1 Ab (-)
ALP 169 IU/L AMA (-)
cGTP 85 IU/L HBs Ag (-)
Total bilirubin 1.3 mg/dL HBc Ab (?)
Cholinesterase 290 IU/L HBV-DNA (-)
HCV-RNA 3.3 log IU/mL
Genotype 1b
HLA-DR 9, 15
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123daily administration of 5 mg has continued to date. Con-
sequently, her ALT and IgG levels have remained within
the normal range (Fig. 4).
Discussion
We have reported two patients with features of AIH
together with HCV infection, who were successfully trea-
ted with PEG-IFN plus RBV therapy preceded by and
combined with steroid administration. This therapeutic
challenge may represent one approach for hepatitis in
patients with combined AIH and CHC.
The most important issue in this approach is how to
judge whether the autoimmunity is associated with hepatic
inﬂammation in patients with HCV infection.
CHC patients sometimes become positive for autoanti-
bodies such as ANA, therefore, it is difﬁcult to distinguish
serologically between simple CHC and CHC combined
with AIH. A variety of type 2 AIH, which is characterized
by anti-LKM-1 antibodies in the serum, has been reported
with HCV-associated AIH [11]. However, the positivity
rate of anti-LKM-1 antibodies in Japanese CHC patients is
low [12], and our two cases were actually both negative.
There are some reports indicating the importance of
histological manifestations such as severe piecemeal
Fig. 3 Histological ﬁndings of Case 2 show moderate inﬁltration of lymphocytes and plasma cells in portal areas, interface hepatitis and rosette
formation. a H&E 940, b H&E 9400
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123necrosis, lobular hepatitis, multinucleated giant cells, and
moderate or severe inﬁltration of plasma cells, which are
microscopic characteristics of AIH, to distinguish CHC
accompanied with AIH from simple CHC [13].
WediagnosedCHCcombinedwithAIHbasedonchanges
in the level of ALT during previous IFN treatment and his-
tological ﬁndings in Case 1, and on other accompanying
autoimmune diseases and histological ﬁndings in Case 2.
However, the treatment strategy for combined AIH/HCV
has not yet been established. It is known that IFN often
induces acute exacerbation of AIH, and occasionally ful-
minant hepatic failure [6–8], therefore, many reports have
recommended CS therapy for these patients [14, 15]. In
contrast, there are some reports showing that IFN therapy is
more effective than CS, even in combined AIH/CHC [16].
Petersen-Benz et al. [17] reported successful treatment of a
case with AIH/CHC overlap syndrome. First, they treated
AIHwithCSforseveralyears,andthenswitchedtoIFNplus
RBV therapy for CHC, and achieved HCV eradication.
However, readministration of CS was required to inhibit
hepatic inﬂammation in this case. Therefore, we planned
pretreatmentwith CSandsubsequentIFNplus RBVtherapy
combined with continued CS for our two cases. PEG-IFN
plus RBV therapy was started at 6 weeks of CS treatment in
Case 1 versus at 13 weeks in Case 2 because the ALT level
did not decrease steadily with CS administration in Case 1.
Asaresult,favorableviral eradication wasachieved without
aggravation of hepatic inﬂammation in both cases.
Careful attention to viral breakthrough caused by the
immunosuppressive effect of CS is required. Indeed, HCV
load increased during CS administration in both of our
cases. Therefore, when this therapeutic regimen is admin-
istered, it is necessary to monitor the ALT level closely
until start of antiviral therapy, so as not to miss any
exacerbation of hepatic inﬂammation.
Judging from the changes in IgG and ALT levels during
CS treatment, it is speculated that the hepatic inﬂammation
in Case 1 was caused by both HCV and autoimmunity,
whereas that in Case 2 was mainly caused by AIH.
Therefore, after termination of IFN plus RBV therapy, we
attempted to stop CS treatment in Case 1, but continued a
low dose PSL in Case 2.
In conclusion, although antiviral therapy combined with
CS needs to be carefully applied, it may represent a
worthwhile treatment for CHC patients with clinical and
histological characteristics of AIH.
Conﬂict of interest The authors declare that they have no conﬂict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Jadali Z, Alavian SM. Autoimmune diseases co-existing with
hepatitis C virus infection. Iran J Allergy Asthma Immunol. 2010;
9:191–206.
2. TodaG,ZeniyaM,WatanabeF,ImawariM,KiyosawaK,Nishioka
M, et al. Present status of autoimmune hepatitis in Japan—corre-
latingthecharacteristicswithinternationalcriteriainanareawitha
high rate of HCV infection. Japanese National Study Group of
Autoimmune Hepatitis. J Hepatol. 1997;26:1207–12.
3. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of
corticosteroid therapy in active chronic hepatitis. QJ Med. 1971;
40:159–85.
4. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG,
Gitnic ´k GL, Elveback IR, et al. Clinical, biochemical, and his-
tological remission of severe chronic active liver disease: a
controlled study of treatments and early prognosis. Gastroenter-
ology. 1972;63:820–33.
5. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of
prednisone and azathioprine in active chronic hepatitis. Lancet.
1973;1:735–7.
6. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation
of liver disease during interferon alfa therapy for chronic hepatitis
C. Gastroenterology. 1992;102:1406–8.
7. Kogure T, Ueno Y, Fukushima K, Nagasaki F, Inoue J, Kakazu E,
et al. Fulminant hepatic failure in a case of autoimmune hepatitis
in hepatitis C during peg-interferon-alpha 2b plus ribavirin
treatment. World J Gastroenterol. 2007;13:4394–7.
8. Coriat R, Podevin P. Fulminant autoimmune hepatitis after suc-
cessful interferon treatment in an HIV-HCV co-infected patient.
Int J STD AIDS. 2008;19:208–10.
9. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK,
Cancado EL, et al. International Autoimmune Hepatitis Group
Report: review of criteria for diagnosis of autoimmune hepatitis.
J Hepatol. 1999;31:929–38.
10. Hennes EM, Zeniya M, Czaja AJ, Pare ´s A, Dalekos GN, Krawitt
EL, et al. International Autoimmune Hepatitis Group. Simpliﬁed
criteria for the diagnosis of autoimmune hepatitis. Hepatology.
2008;48:169–76.
11. Bai L, Lu HY, Feng ZR, Yu M, Li WG, Gong WB, et al.
Detection and the production mechanism of antinuclear anti-
bodies (ANA) and anti-liver/kidney microsomal type 1 antibodies
(anti-LKM1) in patients with chronic hepatitis C. Zhonghua Shi
Yan He Lin Chuang Bing Du Xue Za Zhi. 2009;23:278–81.
12. Nishioka M, Morshed SA, Kono K, Himoto T, Parveen S, Arima
K, et al. Frequency and signiﬁcance of antibodies to P450IID6
protein in Japanese patients with chronic hepatitis C. J Hepatol.
1997;26:992–1000.
13. Carpenter HA, Czaja AJ. The role of histologic evaluation in the
diagnosis and management of autoimmune hepatitis and its
variants. Clin Liver Dis. 2002;6:685–705.
14. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M.
Results of steroid-based therapy for the hepatitis C-autoimmune
hepatitis overlap syndrome. Am J Gastroenterol. 2001;96:2984–91.
15. Ballary S, Schiano T, Hartman G, Black M. Chronic hepatitis
with combined features on autoimmune chronic hepatitis and
chronic hepatitis C: favorable response to predonisone and aza-
thioprine. Ann Intern Med. 1995;123:32–4.
16. Magrin S, Craxi A, Fabiano C, Fiorentino G, Almasio P, Palazzo
U, et al. Hepatitis C virus replication in ‘autoimmune’ chronic
hepatitis. J Hepatol. 1991;13:364–7.
17. Petersen-Benz C, Kasper HU, Dries V, Goeser T. Differential
efﬁcacy of corticosteroids and interferon in a patient with chronic
hepatitis C-autoimmune hepatitis overlap syndrome. Clin Gas-
troenterol Hepatol. 2004;2:440–3.
Clin J Gastroenterol (2012) 5:141–145 145
123